Merck’s Gardasil is a potent vaccine against HPV, a sexually transmitted disease that can cause cervical cancer. But until recently, cost and production constraints limited its reach. Merck has now committed more than $1 billion to expand capacity, with a focus on underserved countries. Merck more than doubled global supply of Gardasil between 2017 and 2020 and is on track to do so again by 2023.
Courtesy of Merck
Company Information
As of 4/4/23
Country
U.S.
Headquarters
Kenilworth, N.J.
Industry
Pharmaceuticals
CEO
Robert Davis
Website
Company Type
Public
Ticker
MRK
Revenues ($M)
$59,283
Profits ($M)
$14,519
Market Value ($M)
$264,267
Employees
68,000
Figures are for fiscal year ended Dec. 31, 2022. Market value as of March 17, 2023. Sources: S&P Global; Bloomberg.
Change the World
Impact Segment
Public Health
Sector
Health Care
Prior Year Rank
-
Historical Data
| Year | Revenues ($M) | Profits ($M) |
|---|---|---|
| 2018 | $40,122 | $2,394 |
Lists ranking Merck
Latest news for Merck
- Health
Overwhelmed by a massive outbreak, China authorizes emergency use of Merck COVID pill LagevrioDecember 30, 2022, 10:11 AM UTC - Finance
The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021August 15, 2022, 10:15 PM UTC
